Achieve’s cytisinicline CRL cited a prior facility and incomplete labeling, not clinical failure. Why this CMC rejection ...
Unicycive OLC received a second FDA CRL over third-party manufacturing deficiencies. The case shows why CMC risk now drives ...
AlzeCure did not prove ACD856 works in Alzheimer’s patients. It proved something else: early clinical safety, brain exposure, and a novel CNS mechanism can still be valuable enough to move a small ...
Viridian’s Lumvoa approval is not only a new thyroid eye disease launch. It is the first real crack in Amgen’s Tepezza-controlled market. The label is broad, the course is shorter, and the diplopia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results